Reckitt Benckiser Group (OTCMKTS:RBGLY) Stock Price Crosses Below 200-Day Moving Average of $14.88

Shares of Reckitt Benckiser Group plc (OTCMKTS:RBGLY) passed below its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $14.88 and traded as low as $13.45. Reckitt Benckiser Group shares last traded at $13.54, with a volume of 1,040,008 shares.

Analyst Ratings Changes

Several research firms have issued reports on RBGLY. BNP Paribas downgraded Reckitt Benckiser Group from a “neutral” rating to an “underperform” rating in a report on Tuesday, September 12th. Berenberg Bank lowered Reckitt Benckiser Group from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. Barclays decreased their target price on Reckitt Benckiser Group from GBX 7,700 ($94.56) to GBX 7,400 ($90.88) in a research report on Monday, October 2nd. Finally, HSBC lowered Reckitt Benckiser Group from a “buy” rating to a “hold” rating in a research report on Thursday, October 26th. One analyst has rated the stock with a sell rating, four have issued a hold rating and one has issued a buy rating to the stock. According to MarketBeat.com, Reckitt Benckiser Group currently has an average rating of “Hold” and a consensus target price of $7,065.00.

Reckitt Benckiser Group Stock Up 0.8 %

The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.36 and a current ratio of 0.54. The stock has a 50-day moving average of $14.01 and a 200-day moving average of $14.88.

About Reckitt Benckiser Group

Reckitt Benckiser Group plc manufactures and sells health, hygiene, and nutrition products worldwide. It offers acne treatment creams, facial washes, and cleansing pads; germ protection products; condoms; heartburn and indigestion solutions; joints health products; chest congestion, cough, and sinus remedies; vaginal care routine products; sore throat medications; and hair removal products under the Clearasil, Dettol, Durex, Gaviscon, Nurofen, Mucinex, Queen V, Strepsils, and Veet brands.